Therapeutic approaches to anaerobic infection.
D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002228:Carbenicillin / Q000627:therapeutic use; D002440:Cefoxitin / Q000627:therapeutic use; D002513:Cephamycins / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D005831:Genital Diseases, Female / Q000188:drug therapy; D006089:Gram-Negative Anaerobic Bacteria; D006801:Humans; D008297:Male; D009070:Moxalactam; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013492:Suppuration; D013982:Ticarcillin / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002513:Cephamycins; D004338:Drug Combinations; D002981:Clindamycin; D002701:Chloramphenicol; D002440:Cefoxitin; D013982:Ticarcillin; D002228:Carbenicillin; D009070:Moxalactam